Eisai, Purdue's insomnia candidate improves postural stability in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 108 showing that both doses of insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of improving postural stability as measured by mean changes from baseline in body sway vs. zolpidem ER. Data were presented at the Associated Professional Sleep Societies meeting in Baltimore.

The double-blind, crossover, U.S. trial enrolled 56 healthy volunteers ages 55 and older to receive a single dose of placebo, 5 or 10 mg oral lemborexant or zolpidem ER...